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Objective: To investigate the effects of pioglitazone on controlled ovarian stimulation (COS), IVF outcomes, and follicular fluid (FF) cytokine 
concentrations in patients with polycystic ovary syndrome (PCOS).
Methods: Eighty-six infertile patients with PCOS resistant to clomiphene citrate were randomized to receive pioglitazone (30 mg/day) or pla-
cebo on the starting day of oral contraceptive (OC) pretreatment, followed by an IVF protocol using a GnRH antagonist. Pioglitazone or placebo 
was administered once daily from the starting day of OC to the day of hCG injection. 
Results: Total dose and days of recombinant follicle-stimulating hormone administered, and the numbers of retrieved and mature oocytes, 
were significantly lower in the pioglitazone group than in the control group. FF tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) concen-
trations at oocyte retrieval were also significantly lower in the pioglitazone group. The clinical pregnancy rate was higher and the incidence of 
severe ovarian hyperstimulation syndrome was lower in the pioglitazone group, but the differences were not statistically significant.
Conclusion: Pioglitazone reduces FF TNF-α and IL-6 levels, and may improve ovarian response to COS in patients with PCOS.
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Introduction
Polycystic ovary syndrome (PCOS), the most common endocrine-
gynecological disorder in women of reproductive age, is character-
ized by menstrual irregularity, infertility, obesity and hyperandrogen-
ism [1,2]. Although the exact pathogenesis of these complex clinical 
presentations is not completely understood, insulin resistance is con-
sidered important [3]. Patients with PCOS are therefore treated with 
insulin sensitizing agents such as the biguanide metformin, and thia-
zolidinediones have been tested in these patients. Although trogli-
tazone is the most studied thiazolidinedione, it was withdrawn from 
the market because of serious hepatotoxicity [2]. 
We previously investigated the effects of pioglitazone, a new thia-
zolidinedione derivative, on ovarian stimulation, IVF outcome, and 
intraovarian stromal blood flow in patients with PCOS. We found that 
pioglitazone therapy reduced intraovarian stromal blood flow and 
may improve ovarian stimulation response and IVF outcomes in PCOS 
patients [4].
Chronic low grade inflammation and imbalances between pro- and 
anti-inflammatory cytokines may also be involved in the pathogene-
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sis of PCOS. Tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) 
are principal pro-inflammatory mediators, and have been shown to 
influence ovarian function, ovulation, fertilization and implantation 
in women with PCOS [5]. In addition, the concentrations of circulat-
ing inflammatory markers have been correlated with obesity and in-
sulin resistance in patients with PCOS [6]. Furthermore, patients with 
PCOS were found to have higher serum and follicular fluid (FF) con-
centrations of TNF-α and IL-6 than women without PCOS [7]. We there-
fore investigated the effect of pioglitazone on the concentrations of 
TNF-α and IL-6 in ovarian FF in women with PCOS undergoing IVF-ET.
Methods
1. Patients
Eighty-six infertile women with PCOS were prospectively recruited 
to this randomized study, which was performed at a university-based 
infertility clinic at the Asan Medical Center, Seoul, South Korea. Pa-
tients were diagnosed with PCOS based on the revised diagnostic 
criteria of the 2003 Rotterdam consensus [8]. All had failed to ovulate 
or conceive after repeated treatment with up to 5 cycles of 150 mg/
day clomiphene citrate (CC) on each of 5 days. They don’t have any 
other etiologic factors of infertility. All patients were in good health 
with normal thyroid, hepatic, and renal functions, and all had experi-
enced spontaneous onset of puberty and normal sexual develop-
ment. Blood samples were collected from each patient on menstrual 
cycle day (MCD) 3 for basal measurements of glucose, sex hormones, 
insulin-like growth factor-1 (IGF-1) and DHEAS. Patient characteristics 
are shown in Table 1.
Sample size was determined in test of superiority. Patients were ran-
domized to treatment with pioglitazone (n=43) or placebo (n=43) 
using sealed envelopes. Prior to ovarian stimulation, all patients were 
pretreated for 3 weeks with a monophasic oral contraceptive (OC, Di-
ane35; Schering AG, Berlin, Germany). Patients were prescribed 30 
mg pioglitazone (Actos; Takeda, Osaka, Japan) or placebo once daily 
from the starting day of OC to the day of hCG (Ovidrel; Serono, Gene-
va, Switzerland) injection. 
All patients provided written informed consent, and the study pro-
tocol was approved by the institutional review board of the Universi-
ty of Ulsan College of Medicine, Asan Medical Center.
2. Ovarian stimulation 
Controlled ovarian stimulation (COS) was induced with 50-150 IU of 
recombinant human follicle-stimulating hormone (rhFSH, Puregon; 
Organon, Oss, Netherland), starting on MCD 3. Initial dose of rhFSH 
was determined according to the patient’s age and body mass index. 
The dose of rhFSH was adjusted every 3-4 days based on ovarian re-
sponse, as determined by ultrasound scans. When the lead follicle 
reached a diameter of 13 to 14 mm, we started treatment with a GnRH 
antagonist (Cetrotide; ASTA Media, Frankfurt am Main, Germany), 
continuing up to the day of hCG injection. When one or more follicles 
reached a mean diameter of ≥18 mm, 250 μg hCG was administered 
subcutaneously to induce follicular maturation. Oocytes were re-
trieved 35 to 36 hours later, with one to four embryos transferred to 
the uterus three days later.
The luteal phase was supplemented with 90 mg of vaginal proges-
terone gel (Crinone 8%; Serono, SA, Geneva, Switzerland) once daily, 
starting on the day of oocyte retrieval. Pregnancies were determined 
by an increase in serum β-hCG concentration and transvaginal ultra-
sonographic evidence of a gestational sac. Serum concentrations of 
β-hCG were measured 11 days after embryo transfer (ET) by radioim-
munoassay using an hCG MAIAclone kit (Serono Diagnostics, Wok-
ing, UK), with inter- and intraassay variances of <10% and 5%, re-
spectively. A clinical pregnancy was defined as the presence of a ges-
tational sac on ultrasonography.
3. FF collection and biochemical assays (outcome measures)
Ovarian FFs were obtained from at least 2 follicles (range, 17-21 mm) 
at oocyte retrieval from each patient. Each follicle was aspirated sep-
arately, and fluids were collected in 15 mL conical tubes. A pooled FF 
sample from each patient was obtained by combining equal aliquots 
from two or more fluid collection tubes. Each fluid sample was cen-
trifuged (2,000 g) to remove cell debris, and all supernatants were 
stored at -20°C.
The concentrations of IL-6 and TNF-α in each FF sample were mea-
sured by a solid-phase enzyme-linked immunosorbent assay (Med-
Table 1. Patient characteristics
Pioglitazone 
group
Control 
group p-value
No. of patients 43 43
Age of patients (yr) 32.0±2.7 31.4±3.1 NS
a
Infertility duration (yr) 3.3±1.3 3.2±1.2 NS
a
BMI (kg/m
2) 22.6±2.6 22.4±2.6 NS
a
No. of nulliparous (%) 30 (69.8%) 28 (65.1%) NS
b
Fasting glucose (mg/dL) 102.2±21.7 101.1±18.3 NS
a
2  hr glucose after 75 g glucose 
load (mg/dL)
135.3±27.6 129.5±30.1 NS
a
Endocrine profile
   Basal FSH (IU/L) 4.3±1.3 4.5±1.0 NS
a
   Basal LH (IU/L) 7.5±1.7 7.2±1.3 NS
a
   Basal T (ng/mL) 1.0±0.4 0.9±0.5 NS
a
   Basal free T (pg/mL) 1.9±1.1 1.7±0.9 NS
a
   IGF-1 (ng/mL) 308.3±55.7 315.1±60.1 NS
a
   DHEAS (ng/mL) 2,178.7±322.5 2,111.1±275.7 NS
a
Values are means±SD. 
BMI, body mass index; IGF, insulin-like growth factor; NS, not significant.
aStudent’s t-test; 
bChi-square test.  doi: 10.5653/cerm.2011.38.2.98
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genix Diagnostics, Fleurus, Belgium). Intraassay coefficients of varia-
tion were 3.3% for TNF-α and 4.2% for IL-6. 
4. Statistical analysis
Results are reported as the mean±SD. Student’s t-test was used to 
compare the mean values. The Chi-square test and Fisher’s exact test 
were used to compare the fractions. Statistical significance was de-
fined as p<0.05. The SPSS statistical package for Windows, ver. 11.0 
(SPSS Inc., Chicago, IL, USA) was used for all analyses.
Results
Baseline patient demographic characteristics and baseline hormone 
concentrations were similar in the two groups (Table 1). There were 
no differences in fasting plasma glucose concentrations and two hour 
plasma glucose after 75 g glucose load. Ovarian stimulation charac-
teristics are summarized in Table 2. The duration of stimulation (p< 
0.001) and the total gonadotropin dose (p=0.002) were significantly 
lower in the pioglitazone than in the control group, as were the num-
bers of follicles ≥14 mm (p=0.002) and 11 to 13 mm (p<0.001). The 
numbers of retrieved oocytes, mature oocytes and fertilized oocytes 
were also significantly lower in the pioglitazone group (p<0.001 
each), but there was no difference in the numbers of grade I or II em-
bryos (4.5±2.0 vs. 4.1±2.1). The clinical pregnancy rate (44.8% vs. 
41.8%) and live birth rate (44.2% vs. 34.9%) were higher in the piogli-
tazone than in the control group, but these differences were not sta-
tistically significant. Moreover, the incidence of severe ovarian hyper-
stimulation syndrome (OHSS) was lower in the pioglitazone group 
(2.3% vs. 9.3%), but the difference was not statistically significant.
TNF-α and IL-6 concentrations in the FF of both groups are shown 
in Table 3. Both TNF-α (32.1±10.2 pg/mL vs. 40.1±13.5 pg/mL, p= 
0.003) and IL-6 (18.9±6.0 pg/mL vs. 23.9±7.5 pg/mL, p=0.001) con-
centrations were significantly lower in the pioglitazone than in the 
control group. 
Discussion
We have shown here that treatment with pioglitazone during 3 
weeks of OC pretreatment and the period of ovarian stimulation re-
duced the concentrations of TNF-α and IL-6 in the FF of women with 
PCOS undergoing IVF. Although, in agreement with our previous re-
sults, we found that the number of retrieved oocytes was lower in 
the pioglitazone than in the control group, the development of grade 
I or II embryos was similar [4]. We also found that clinical pregnancy 
and live birth rates tended to be higher, and that serious complica-
tions such as OHSS tended to be lower, in the pioglitazone group.
TNF-α and IL-6 are important pro-inflammatory cytokines that may 
influence ovarian function and other reproductive processes [5]. These 
cytokines have been associated with the pathogenesis of endome-
triosis, a common benign gynecological disorder. For example, TNF-α 
concentrations in peritoneal fluid were found to be higher in women 
with than without endometriosis [9], suggesting that TNF-α may have 
a role in the establishment, maintenance and progression of endo-
metriosis. IL-6 concentrations have also been reported to be higher 
in women with endometriosis [10], as well as in women with unex-
plained infertility [11]. Moreover, both TNF-α and IL-6 concentrations 
were found to be higher in PCOS patients than in body mass index-
matched controls [6].
Table 2. Controlled ovarian stimulation results and IVF outcomes
Pioglitazone 
group
Control 
group p-value
No. of cycles initiated 43 43
No. of ET cycles  43 43
Days of rhFSH  10.5±1.4 11.9±2.0 <0.001
a
Total dose of rhFSH  1,505.8±431.0 1,860.1±577.5 0.002
a
On the day of hCG injection
   No. of follicles (≥14 mm) 9.2±2.7 11.7±4.4 0.002
a
   No. of follicles (11-13 mm) 6.5±2.1 10.5±4.0 <0.001
a
   Estradiol (pg/mL) 1,785±443.2  2,372±621.2 <0.001
a
No. of oocytes retrieved 12.4±3.2 16.7±7.0 <0.001
a
No. of mature oocytes 10.0±2.7 13.8±6.0 <0.001
a
No. of fertilized oocytes 9.9±2.6 13.6±5.5 <0.001
a
Fertilization rate (%) 82.3±10.7 81.5±13.9 NS
a
No. of grade I or II embryos 4.5±2.0 4.1±2.1 NS
a
No. of embryos frozen 3.3±3.0 4.4±5.5 NS
a
No. of embryos transferred 3.4±0.5 3.3±0.8 NS
a
Clinical PR/cycle initiated (%) 48.8 (21/43) 41.9 (18/43) NS
b
Multiple PR/clinical preg. (%) 19.0 (4/21) 16.7 (3/18) NS
b
Embryo implantation rate (%) 18.2 (27/148) 15.4 (22/143) NS
b
Miscarriage rate (%) 9.5 (2/21) 16.7 (3/18) NS
b
Live birth rate/ ET (%) 44.2 (19/43) 34.9 (15/43) NS
b
Severe OHSS incidence (%) 2.3 (1/43) 9.3 (4/43) NS
b
Values are means±SD. 
ET, embryo transfer; rhFSH, recombinant human follicle stimulating hormone; 
PR, pregnancy rate; OHSS, ovarian hyperstimulation syndrome; NS, not sig-
nificant.
aStudent’s t-test; 
bChi-square test or Fisher’s exact test.
Table 3. TNF-α, IL-6 concentrations in the follicular fluid of patients 
with PCOS
Pioglitazone group 
(n=43)
Control group
(n=43) p-value
TNF-α (pg/mL) 32.1±10.2 40.1±13.5 0.003
a
IL-6 (pg/mL) 18.9±6.0 23.9±7.5 0.001
a
Values are means±SD. 
TNF-α, tumor necrosis factor-α; IL-6, inter leukin-6; PCOS, polycystic ovary 
syndrome.
aStudent’s t-test. www.eCERM.org
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Due to the heterogeneous features of PCOS, its diagnosis and man-
agement remain unclear. Although the exact pathophysiology of 
PCOS is also unclear, hyperandrogenism and insulin resistance have 
been found to contribute to its etiology. Inflammatory cytokines 
closely linked to obesity and insulin resistance may be important in 
the pathogenesis of PCOS [12]. Women with PCOS were found to 
have chronic low grade inflammation, as determined by their con-
centrations of C-reactive protein [13], which is associated with risk 
factors of cardiovascular disease such as dyslipidemia, glucose intol-
erance, type 2 diabetes, hypertension and obesity [6]. Adipose tissue 
has been found to be the main source of TNF-α and IL-6 [14]. Infertile 
women with PCOS were found to have higher serum and FF concen-
trations of TNF-α and IL-6 than control women, suggesting that gran-
ulosa cells produce both cytokines [7]. Furthermore, a polymorphism 
in the IL-6 promoter region may be related to insulin resistance and 
metabolic abnormalities in PCOS [5].
Insulin-sensitizing agents have been investigated for their ability to 
manage insulin resistance, irregular menstruation, infertility and obe-
sity in women with PCOS. The biguanide metformin has been recom-
mended for PCOS patients with glucose intolerance, body mass in-
dex >35 kg/m
2, or resistance to clomiphene citrate [4]. Another type 
of insulin sensitizer, troglitazone, a thiazolidinedione, has also been 
tested in these patients, but it was removed from the market because 
of serious liver toxicity. Two other thiazolidinediones, pioglitazone 
and rosiglitazone, are still being investigated in patients with PCOS; 
both agents have been found to improve menstrual irregularity and 
insulin sensitivity. Moreover, both have better safety profiles than 
troglitazone [1]. Despite their ability to enhance ovulation rate and 
improve fertility, they have not been tested in clinical trials of ovula-
tion induction and IVF outcomes [15].
Our previous study was the first to assess the effect of pioglitazone 
on ovulation induction and IVF outcome in PCOS patients [4]. Mea-
surements of the resistance index of the intraovarian stromal artery 
on the day of hCG injection showed that pioglitazone diminished 
blood flow in the ovarian stroma, enhanced the response to ovarian 
stimulation, and improved IVF outcomes in PCOS patients resistance 
to CC treatment. This study showed similar COS and IVF outcomes, 
except that the number of fertilized oocytes was significantly lower 
in the pioglitazone than in the control group, a difference that may 
be due to larger numbers of subjects in this study.
Thiazolidinediones bind to peroxisome proliferator-activated re-
ceptor gamma (PPAR-γ), which is located primarily in adipose tissue. 
Activation of this receptor decreases insulin resistance by enhancing 
fatty acid uptake into adipose tissue, producing more adiponectin 
and decreasing inflammatory mediators such as TNF-α and IL-6. PPAR- 
γ activation suppresses these inflammatory cytokines by negatively 
regulating macrophages in adipose tissue [1,16,17]. Moreover, the 
thiazolidinediones rosiglitazone was recently shown to significantly 
increase PPAR-γ mRNA and decrease TNF-α in human granulosa-lu-
tein cells in vitro, and to decrease IL-6 secretion, although not signifi-
cantly [18]. In ovaries, PPAR-γ is expressed more by granulosa cells 
than by theca cells and corpora lutea [19], findings consistent with 
our results. Pioglitazone may act on PPAR-γ present on granulosa 
cells and reduce TNF-α and IL-6 in FF. Cytokines within the ovary may 
act in an autocrine or paracrine manner, regulating follicular matura-
tion and subsequent embryonic development [20]. Thus, by reduc-
ing TNF-α and IL-6 concentrations, pioglitazone may increase clinical 
pregnancy and live birth rates.
In conclusion, chronic low grade inflammation, represented by 
TNF-α and IL-6, may contribute to the pathophysiology of PCOS and 
may have a harmful effect on COS and IVF. Thus, relieving inflamma-
tion may be beneficial for PCOS patients undergoing IVF treatments. 
This study is the first to show that pioglitazone decreases FF concen-
trations of TNF-α and IL-6, resulting in better IVF outcomes. Further 
studies are needed to establish the effectiveness and long-term safe-
ty of pioglitazone treatment in women with PCOS.
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